UZPRUVO

This brand name is authorized in Austria, Croatia, Estonia, France, Lithuania, Romania.

Active ingredients

The drug UZPRUVO contains one active pharmaceutical ingredient (API):

1	Ustekinumab UNII FU77B4U5Z0 - USTEKINUMAB
	Ustekinumab is a fully human IgG1κ monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin (IL)-12 and IL-23. Ustekinumab inhibits the bioactivity of human IL-12 and IL-23 by preventing p40 from binding to the IL-12R1 receptor protein expressed on the surface of immune cells. Abnormal regulation of IL 12 and IL 23 has been associated with immune mediated diseases, such as psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
	Read more about Ustekinumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
UZPRUVO Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC05	Ustekinumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3062977, 3062988
FR	Base de données publique des médicaments	62575246, 62685842
LT	Valstybinė vaistų kontrolės tarnyba	1098624, 1098625
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69959001, W69960001